| Quarter | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| 107 | 139 | 126 | 139 | 139 | 210 | 175 | |
Growth YoY Revenue Growth YoY% | 17.9 | -0.1 | 10.6 | 51.3 | 25.4 | ||
| 88 | 119 | 107 | 115 | 115 | 177 | 133 | |
| 19 | 20 | 19 | 23 | 24 | 33 | 41 | |
OPM OPM% | 17.3 | 14.4 | 14.9 | 16.7 | 17.2 | 15.6 | 23.6 |
| 2 | 2 | 3 | 3 | 3 | 4 | 3 | |
Interest Expense Interest ExpenseCr | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 2 | 2 | 2 | 2 | 2 | 3 | 2 |
PBT PBTCr | 19 | 22 | 22 | 26 | 26 | 37 | 44 |
| 3 | 3 | 3 | 8 | 6 | 9 | 11 | |
| 14 | 16 | 16 | 17 | 18 | 26 | 31 | |
Growth YoY PAT Growth YoY% | 16.8 | 3.3 | 9.7 | 55.4 | 72.2 | ||
NPM NPM% | 13.2 | 11.6 | 13.1 | 12.0 | 13.0 | 12.3 | 17.8 |
| 10.4 | 9.4 | 7.8 | 7.5 | 7.8 | 11.0 | 13.0 |
| Quarter | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| 107 | 139 | 126 | 139 | 139 | 210 | 175 | |
Growth YoY Revenue Growth YoY% | 17.9 | -0.1 | 10.6 | 51.3 | 25.4 | ||
| 88 | 119 | 107 | 115 | 115 | 177 | 133 | |
| 19 | 20 | 19 | 23 | 24 | 33 | 41 | |
OPM OPM% | 17.3 | 14.4 | 14.9 | 16.7 | 17.2 | 15.6 | 23.6 |
| 2 | 2 | 3 | 3 | 3 | 4 | 3 | |
Interest Expense Interest ExpenseCr | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 2 | 2 | 2 | 2 | 2 | 3 | 2 |
PBT PBTCr | 19 | 22 | 22 | 26 | 26 | 37 | 44 |
| 3 | 3 | 3 | 8 | 6 | 9 | 11 | |
| 14 | 16 | 16 | 17 | 18 | 26 | 31 | |
Growth YoY PAT Growth YoY% | 16.8 | 3.3 | 9.7 | 55.4 | 72.2 | ||
NPM NPM% | 13.2 | 11.6 | 13.1 | 12.0 | 13.0 | 12.3 | 17.8 |
| 10.4 | 9.4 | 7.8 | 7.5 | 7.8 | 11.0 | 13.0 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Revenue RevenueCr | 114 | 131 | 133 | 166 | 197 | 246 | 265 | 349 | 385 |
Growth Revenue Growth% | 15.3 | 0.9 | 25.0 | 19.1 | 24.4 | 7.8 | 31.9 | 38.4 | |
| 108 | 123 | 122 | 153 | 178 | 206 | 223 | 292 | 310 | |
| 6 | 9 | 11 | 13 | 19 | 39 | 42 | 57 | 74 | |
OPM OPM% | 4.9 | 6.7 | 8.1 | 7.8 | 9.6 | 16.1 | 15.8 | 16.2 | 19.3 |
| 6 | 4 | 2 | 2 | 2 | 3 | 6 | 7 | 7 | |
Interest Expense Interest ExpenseCr | 3 | 3 | 3 | 3 | 3 | 1 | 0 | 1 | 0 |
Depreciation DepreciationCr | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 |
PBT PBTCr | 5 | 6 | 6 | 8 | 15 | 37 | 44 | 58 | 81 |
| 1 | 2 | 1 | 2 | 3 | 6 | 11 | 14 | 20 | |
PAT PATCr | 4 | 4 | 5 | 6 | 12 | 30 | 33 | 44 | 57 |
Growth PAT Growth% | 15.3 | 15.0 | 22.7 | 107.6 | 146.6 | 9.6 | 32.6 | 64.2 | |
NPM NPM% | 3.2 | 3.2 | 3.6 | 3.6 | 6.2 | 12.3 | 12.5 | 12.6 | 14.8 |
| 8.4 | 9.7 | 3.7 | 4.6 | 9.5 | 17.7 | 14.9 | 18.6 | 23.9 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Revenue RevenueCr | 114 | 131 | 133 | 166 | 197 | 246 | 265 | 349 | 385 |
Growth Revenue Growth% | 15.3 | 0.9 | 25.0 | 19.1 | 24.4 | 7.8 | 31.9 | 38.4 | |
| 108 | 123 | 122 | 153 | 178 | 206 | 223 | 292 | 310 | |
| 6 | 9 | 11 | 13 | 19 | 39 | 42 | 57 | 74 | |
OPM OPM% | 4.9 | 6.7 | 8.1 | 7.8 | 9.6 | 16.1 | 15.8 | 16.2 | 19.3 |
| 6 | 4 | 2 | 2 | 2 | 3 | 6 | 7 | 7 | |
Interest Expense Interest ExpenseCr | 3 | 3 | 3 | 3 | 3 | 1 | 0 | 1 | 0 |
Depreciation DepreciationCr | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 |
PBT PBTCr | 5 | 6 | 6 | 8 | 15 | 37 | 44 | 58 | 81 |
| 1 | 2 | 1 | 2 | 3 | 6 | 11 | 14 | 20 | |
PAT PATCr | 4 | 4 | 5 | 6 | 12 | 30 | 33 | 44 | 57 |
Growth PAT Growth% | 15.3 | 15.0 | 22.7 | 107.6 | 146.6 | 9.6 | 32.6 | 64.2 | |
NPM NPM% | 3.2 | 3.2 | 3.6 | 3.6 | 6.2 | 12.3 | 12.5 | 12.6 | 14.8 |
| 8.4 | 9.7 | 3.7 | 4.6 | 9.5 | 17.7 | 14.9 | 18.6 | 23.9 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 4 | 4 | 4 | 13 | 13 | 21 | 21 | 24 | 24 |
Reserves ReservesCr | 17 | 21 | 22 | 19 | 37 | 143 | 174 | 252 | 280 |
| 34 | 34 | 35 | 54 | 54 | 38 | 30 | 44 | ||
| 18 | 18 | 19 | 9 | 7 | 3 | 3 | 3 | ||
| 73 | 77 | 81 | 95 | 111 | 205 | 228 | 322 | 346 | |
| 43 | 48 | 50 | 64 | 78 | 163 | 154 | 155 | ||
| 30 | 29 | 31 | 31 | 33 | 41 | 74 | 167 | ||
| 73 | 77 | 81 | 95 | 111 | 205 | 228 | 322 | 346 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 4 | 4 | 4 | 13 | 13 | 21 | 21 | 24 | 24 |
Reserves ReservesCr | 17 | 21 | 22 | 19 | 37 | 143 | 174 | 252 | 280 |
| 34 | 34 | 35 | 54 | 54 | 38 | 30 | 44 | ||
| 18 | 18 | 19 | 9 | 7 | 3 | 3 | 3 | ||
| 73 | 77 | 81 | 95 | 111 | 205 | 228 | 322 | 346 | |
| 43 | 48 | 50 | 64 | 78 | 163 | 154 | 155 | ||
| 30 | 29 | 31 | 31 | 33 | 41 | 74 | 167 | ||
| 73 | 77 | 81 | 95 | 111 | 205 | 228 | 322 | 346 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| 6 | 5 | 5 | 15 | 8 | 11 | 25 | 19 | |
| -4 | -2 | -6 | -4 | -4 | -82 | -9 | -49 | |
| -1 | -2 | -2 | -10 | -4 | 72 | -14 | 36 | |
Net Cash Flow Net Cash FlowCr | 1 | 1 | -3 | 1 | -1 | 1 | 2 | 6 |
Free Cash Flow Free Cash FlowCr | 2 | 3 | 0 | 11 | 4 | -2 | -12 | -68 |
CFO To PAT CFO To PAT% | 158.1 | 126.5 | 104.9 | 252.3 | 61.9 | 37.5 | 74.6 | 42.5 |
CFO To EBITDA CFO To EBITDA% | 102.4 | 60.4 | 47.1 | 114.6 | 40.0 | 28.7 | 58.9 | 32.9 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| 6 | 5 | 5 | 15 | 8 | 11 | 25 | 19 | |
| -4 | -2 | -6 | -4 | -4 | -82 | -9 | -49 | |
| -1 | -2 | -2 | -10 | -4 | 72 | -14 | 36 | |
Net Cash Flow Net Cash FlowCr | 1 | 1 | -3 | 1 | -1 | 1 | 2 | 6 |
Free Cash Flow Free Cash FlowCr | 2 | 3 | 0 | 11 | 4 | -2 | -12 | -68 |
CFO To PAT CFO To PAT% | 158.1 | 126.5 | 104.9 | 252.3 | 61.9 | 37.5 | 74.6 | 42.5 |
CFO To EBITDA CFO To EBITDA% | 102.4 | 60.4 | 47.1 | 114.6 | 40.0 | 28.7 | 58.9 | 32.9 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 517 | 402 | 852 | 1,403 | |||||
Price To Earnings Price To Earnings | 17.1 | 12.2 | 19.4 | 24.4 | |||||
Price To Sales Price To Sales | 2.1 | 1.5 | 2.4 | 3.6 | |||||
Price To Book Price To Book | 3.2 | 2.1 | 3.1 | 5.1 | |||||
EV To EBITDA EV To EBITDA | 11.6 | 8.4 | 14.7 | 18.7 | |||||
GPM GPM% | 23.9 | 26.5 | 22.2 | 23.6 | 22.8 | 27.6 | 27.8 | 28.3 | 28.3 |
OPM OPM% | 4.9 | 6.7 | 8.1 | 7.8 | 9.6 | 16.1 | 15.8 | 16.2 | 19.3 |
NPM NPM% | 3.2 | 3.2 | 3.6 | 3.6 | 6.2 | 12.3 | 12.5 | 12.6 | 14.8 |
ROCE ROCE% | 16.6 | 18.0 | 16.4 | 19.0 | 23.7 | 21.3 | 22.5 | 21.3 | 26.5 |
ROE ROE% | 17.3 | 16.6 | 18.0 | 18.4 | 24.3 | 18.4 | 17.0 | 15.9 | 18.7 |
ROA ROA% | 5.0 | 5.4 | 6.0 | 6.2 | 11.1 | 14.7 | 14.5 | 13.6 | 16.5 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 517 | 402 | 852 | 1,403 | |||||
Price To Earnings Price To Earnings | 17.1 | 12.2 | 19.4 | 24.4 | |||||
Price To Sales Price To Sales | 2.1 | 1.5 | 2.4 | 3.6 | |||||
Price To Book Price To Book | 3.2 | 2.1 | 3.1 | 5.1 | |||||
EV To EBITDA EV To EBITDA | 11.6 | 8.4 | 14.7 | 18.7 | |||||
GPM GPM% | 23.9 | 26.5 | 22.2 | 23.6 | 22.8 | 27.6 | 27.8 | 28.3 | 28.3 |
OPM OPM% | 4.9 | 6.7 | 8.1 | 7.8 | 9.6 | 16.1 | 15.8 | 16.2 | 19.3 |
NPM NPM% | 3.2 | 3.2 | 3.6 | 3.6 | 6.2 | 12.3 | 12.5 | 12.6 | 14.8 |
ROCE ROCE% | 16.6 | 18.0 | 16.4 | 19.0 | 23.7 | 21.3 | 22.5 | 21.3 | 26.5 |
ROE ROE% | 17.3 | 16.6 | 18.0 | 18.4 | 24.3 | 18.4 | 17.0 | 15.9 | 18.7 |
ROA ROA% | 5.0 | 5.4 | 6.0 | 6.2 | 11.1 | 14.7 | 14.5 | 13.6 | 16.5 |
| Market CapitalizationMkt CapCr | 1,841 | 1,593 | 1,482 | 1,403 | 1,382 | 1,112 | 1,079 |
| Close PriceClose₹ | 1,655.40 | 2,312.00 | 512.65 | 584.85 | 209.27 | 469.95 | 320.15 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 33.99 | 25.87 | 24.43 | 30.64 | 96.70 | 52.83 | |
| Price To SalesPS | 4.14 | 4.04 | 2.80 | 3.65 | 4.60 | 7.18 | 1.64 |
| RevenueRevenueCr | 444 | 395 | 529 | 385 | 301 | 155 | 656 |
| Revenue Growth TTMRev Gr TTM% | 15.2% | 10.6% | 12.6% | 38.4% | 6.4% | 8.7% | 14.3% |
| PAT Growth TTMPAT Gr TTM% | 27.3% | 64.3% | 1.0% | 64.2% | -26.6% | 31.4% | -55.0% |
| Market CapitalizationMkt CapCr | 1,841 | 1,593 | 1,482 | 1,403 | 1,382 | 1,112 | 1,079 |
| Close PriceClose₹ | 1,655.40 | 2,312.00 | 512.65 | 584.85 | 209.27 | 469.95 | 320.15 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 33.99 | 25.87 | 24.43 | 30.64 | 96.70 | 52.83 | |
| Price To SalesPS | 4.14 | 4.04 | 2.80 | 3.65 | 4.60 | 7.18 | 1.64 |
| RevenueRevenueCr | 444 | 395 | 529 | 385 | 301 | 155 | 656 |
| Revenue Growth TTMRev Gr TTM% | 15.2% | 10.6% | 12.6% | 38.4% | 6.4% | 8.7% | 14.3% |
| PAT Growth TTMPAT Gr TTM% | 27.3% | 64.3% | 1.0% | 64.2% | -26.6% | 31.4% | -55.0% |